September 30, 2024

BOLD Innovation That Matters: Episode 3 【Preview Only】

WuXi AppTec was honored to have hosted the BOLD Innovation That Matters: Episode 3 virtual event. Over 30 experts from the life science field joined us to share their bold ideas, bold actions, and progress in tackling global challenges related to cancer, CNS disorders, and rare diseases.

During the event, these experts had thought-provoking discussions on various topics, including Breaking Barriers in Cancer R&D, Overcoming CNS Challenges, and Leading the New Generation in Rare Disease Intervention. They also showcased the latest advancements in treatments for cancer, CNS disorders, and rare diseases. The discussions were led by some of the life science industry’s most inspiring thought leaders and CEOs. Their shared insights addressed innovative approaches to common scientific obstacles that can enable efficiencies across our collective pursuits of breakthroughs for patients.

We want to say a big thank you to all the guest speakers for sharing their valuable insights and knowledge with us. We also appreciate all of you who tuned in to participate and helped make this event such a great success!

WuXi AppTec is committed to fostering innovation as a dedicated enabler, a trusted partner, and an active contributor to advancing breakthroughs for patients. By working together, we can think boldly and act boldly in addressing global health challenges!

We look forward to seeing you at future WuXi AppTec online and in-person events!

EVENTS

WuXi Executive Breakfast in Basel: The Most Important Innovation in Drug R&D May Be How the Industry Works Together

Reflections from the WuXi Executive Breakfast at Swiss Biotech Day

May 11, 2026

READ MORE

FEATURED

From Discovery to IND: A Biology-First Approach to New Modalities

Across complex therapeutic areas, innovators are applying an expanding range of new modalities, from antibody-drug conjugates (ADCs) and bispecific antibodies to peptides, oligonucleotides, and other advanced formats. Yet as the therapeutic toolbox expands, one principle remains central: modality should follow biology...

May 28, 2026

For many years, early oncology programs often began with a familiar question: Can we drug this target? Today, that question has become more nuanced. Once a promising target or pathway is identified, discovery teams also need to determine which modality is most appropriate, which patient population is most likely to benefit, which assay system can generate reliable data, and how early decisions may influence downstream development risk...

May 28, 2026

For Jane Jiang, March was not just a month on the calendar—another time she enjoyed running followed by the familiar mix of tired legs and good energy. Her path, winding through early starts and steady miles, brings a sense of clarity to the races, but also to the people and moments shared along the way...

May 19, 2026

READ MORE